Princess Nourah bint Abdulrahman University, College of Medicine, Department of Basic Science, Riyadh, Saudi Arabia.
King Abdulaziz University, Faculty of Applied Medical Sciences, Department of Medical Laboratory Sciences, Jeddah, Saudi Arabia.
Rev Inst Med Trop Sao Paulo. 2024 Sep 6;66:e55. doi: 10.1590/S1678-9946202466055. eCollection 2024.
Rotavirus, a dsRNA virus in the Reoviridae family, shows a segmented genome. The VP1 gene encodes the RNA-dependent RNA polymerase (RdRp). This study aims to develop a multiepitope-based vaccine targeting RdRp using immunoinformatic approaches. In this study, 100 available nucleotide sequences of VP1-Rotavirus belonging to different strains across the world were retrieved from NCBI database. The selected sequences were aligned, and a global consensus sequence was developed by using CLC work bench. The study involved immunoinformatic approaches and molecular docking studies to reveal the promiscuous epitopes that can be eventually used as active vaccine candidates for Rotavirus. In total, 27 highly immunogenic, antigenic, and non-allergenic T-cell and B-cell epitopes were predicted for the Multiepitope vaccine (MEV) against rotavirus. It was also observed that MEV can prove to be effective worldwide due to its high population coverage, demonstrating the consistency of this vaccine. Moreover, there is a high docking interaction and immunological response with a binding score of -50.2 kcal/mol, suggesting the vaccine's efficacy. Toll-like receptors (TLRs) also suggest that the vaccine is physiologically and immunologically effective. Collectively, our data point to an effective MEV against rotavirus that can effectively reduce viral infections and improve the health status worldwide.
轮状病毒（Rotavirus）是呼肠孤病毒科（Reoviridae）中的一种双链 RNA 病毒，具有分段基因组。VP1 基因编码 RNA 依赖的 RNA 聚合酶（RdRp）。本研究旨在采用免疫信息学方法，针对 RdRp 开发一种多表位疫苗。本研究从 NCBI 数据库中检索到了来自世界各地不同株的 100 个 VP1-轮状病毒的可用核苷酸序列。通过 CLC workbench 对选定的序列进行比对，并开发出一个全球共识序列。该研究采用免疫信息学方法和分子对接研究，以揭示最终可作为轮状病毒活性疫苗候选物的广谱表位。总共预测了 27 个具有高免疫原性、抗原性和非变应原性的 T 细胞和 B 细胞表位，用于针对轮状病毒的多表位疫苗（MEV）。此外，由于其高人群覆盖率，MEV 有望在全球范围内有效，这表明了该疫苗的一致性。此外，对接相互作用和免疫反应很高，结合评分为-50.2 kcal/mol，表明该疫苗具有疗效。 Toll 样受体（TLRs）也表明该疫苗在生理和免疫上是有效的。综上所述，我们的数据表明，针对轮状病毒的有效 MEV 可以有效减少病毒感染，改善全球健康状况。
